Literature DB >> 9225078

Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.

H Myint1, F M Ross, J L Hall, T J Hamblin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9225078     DOI: 10.1016/s0145-2126(97)00070-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature.

Authors:  M Colović; G Janković; J Bila; V Djordjević; P H Wiernik
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

2.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

Review 3.  Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.

Authors:  Soranobu Ninomiya; Nobuhiro Kanemura; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Toshiki Yamada; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

4.  Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities.

Authors:  Eunhee Han; Hyeyoung Lee; Myungshin Kim; Yonggoo Kim; Kyungja Han; Sung-Eun Lee; Hee-Je Kim; Dong-Wook Kim
Journal:  Blood Res       Date:  2014-03-24

5.  Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Authors:  Yuan-Yuan Wang; Wen-Jing Ding; Feng Jiang; Zi-Xing Chen; Jian-Nong Cen; Xiao-Fei Qi; Jian-Ying Liang; Dan-Dan Liu; Jin-Lan Pan; Su-Ning Chen
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.